Daprodustat is indicated for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least four months.
Daprodustat has not been shown to improve quality of life, fatigue, or patient well-being.
Daprodustat is not indicated for use:
• As a substitute for red blood cell transfusions in patients who require immediate correction of anemia.
• For treatment of anemia of chronic kidney disease in patients who are not on dialysis.
from FDA,2023.02